Starling Oncology Inc. Common Stock (STLN)
Stock · NASDAQ · Health Care
$6.43as of 10/16/2026
Price chart
Active signals
High Beta64.9%
RSI Positive Divergence0.5%Support level
$6.11
Industry
Medical/Nursing Services
About STLN
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support…
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- Employees
- 641
- Website
- theoncologyinstitute.com/
Fundamentals
- 1-day range
- $6.34$6.9
- Market cap
- $498.91M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.36
- Dividend yield
- —
- Beta
- 2.42
- Avg. volume
- 1.39M
52-week range
$4.85$7.13
Next earnings: November 9, 2026 · EPS estimate $-0.05confirmed
Forecasts
5 analyst ratings
Buy 91%
Hold 9%
Sell 0%
1-year price forecast
High
$11
+71.2%
Median
$9
+40.1%
Low
$8
+24.5%
Starling Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- STLNStarling Oncology Inc. Common Stock$6.43▼ 7.02%Market cap $498.91MP/E —$4.85$7.13
- SRTAStrata Critical Medical Inc. Class A Common Stock$4.54▲ 4.61%Market cap $494.53MP/E 9.58$3.95$6.5
- AUNAAuna SA Class A Ordinary Shares$5.32▲ 0.38%Market cap $384.87MP/E 83.35$4.09$6.71
- AIRSAirSculpt Technologies Inc. Common Stock$1.27▼ 9.89%Market cap $336.50MP/E —$1.41$12
- SBCSBC Medical Group Holdings Incorporated Common Stock$5.16▼ 2.64%Market cap $305.46MP/E 11.12$2.78$5.61
- AHCOAdaptHealth Corp. Common Stock$6.02▼ 5.79%Market cap $824.20MP/E —$5.21$13.43
- LFMDLifeMD Inc. Common Stock$2.34▼ 4.88%Market cap $164.43MP/E 589.89$2.36$6.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STLN Starling Oncology Inc. Common Stock | $498.91M | — | $6.43 | ▼ 7.02% | $4.85$7.13 |
| SRTA Strata Critical Medical Inc. Class A Common Stock | $494.53M | 9.58 | $4.54 | ▲ 4.61% | $3.95$6.5 |
| AUNA Auna SA Class A Ordinary Shares | $384.87M | 83.35 | $5.32 | ▲ 0.38% | $4.09$6.71 |
| AIRS AirSculpt Technologies Inc. Common Stock | $336.50M | — | $1.27 | ▼ 9.89% | $1.41$12 |
| SBC SBC Medical Group Holdings Incorporated Common Stock | $305.46M | 11.12 | $5.16 | ▼ 2.64% | $2.78$5.61 |
| AHCO AdaptHealth Corp. Common Stock | $824.20M | — | $6.02 | ▼ 5.79% | $5.21$13.43 |
| LFMD LifeMD Inc. Common Stock | $164.43M | 589.89 | $2.34 | ▼ 4.88% | $2.36$6.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Needham Maintains Buy on Starling Oncology, Raises Price Target to $9benzinga · 10/14/2026
- Cedar Grove Capital Q3 2026 Portfolio UpdateSeekingAlpha · 10/7/2026
- Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference ParticipationYahoo · 10/1/2026
- Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-RatingSeekingAlpha · 9/30/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
298.9K
- Hively Brad · August 21, 2026 · Sale298.9K @ $6.51
Institutional Ownership
March 31, 2026
- Total shares held
- 39.58M
- Total value held
- $121.27M
- Institutional holders
- 110
Top holders this quarter
- Unknown4.42M
- Unknown3.48M
- Unknown3.36M
- Unknown2.78M
- Unknown2.46M
- Unknown2.35M
- Unknown1.83M
- Unknown1.76M
- Unknown1.71M
- Unknown1.57M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Starling Oncology reports stronger cash flow and gross profit
Starling Oncology disclosed higher cash flow and gross profit in its latest results. The improvement has prompted analysts to consider a re‑rating of the stock. The company’s financial metrics are now better positioned relative to its recent price range.
Starling Oncology reports stronger cash flow and gross profit. Starling Oncology disclosed higher cash flow and gross profit in its latest results. The improvement has prompted analysts to consider a re‑rating of the stock. The company’s financial metrics are now better positioned relative to its recent price range.